Vanda Pharmaceuticals Inc. (VNDA) has launched NEREUS, the first new prescription medication for motion sickness in over 40 years, targeting a significant market of 65 to 78 million Americans affected by this condition. The FDA approved NEREUS on December 30, 2025, following successful Phase 3 trials that demonstrated its effectiveness in preventing vomiting during travel. As a selective neurokinin-1 receptor antagonist, NEREUS offers a modern treatment option with a straightforward dosing regimen.

The introduction of NEREUS could impact VNDA’s stock performance, especially as the company positions itself in a market with limited competition. The drug is priced at $85 per dose through a direct-to-consumer platform, significantly lower than the standard price of $255, which may enhance its accessibility and adoption among patients.

For market professionals, VNDA’s stock, which closed at $7.00 and saw a 5% increase in after-hours trading, may present an interesting opportunity as the company capitalizes on a newly opened market segment.

Source: nasdaq.com